Prior authorization denied. Now what?
You opened the letter, or the pharmacy called, or the portal message pinged your phone: your prior authorization for Zepbound or Wegovy was denied. It is frustrating. It is not the end of the road. A denial rarely means the medication is off the table for good — it usually means the insurer wants more paperwork, is applying a stricter rule than last year, or is signaling that the plan has narrowed what it covers. None of that is your fault, and none of it requires you to make a decision in the parking lot.
Before we go further: the rest of this page is educational information, not medical advice, and not insurance or legal advice. Your specific plan document and your clinician's judgment govern what applies to you. Save any letters, portal messages, and reference numbers from the insurer in one folder as you go — the appeal process rewards good paperwork more than it rewards the loudest phone call.
From here you have two legitimate paths. The first is to fight the denial through the formal appeal process, which can take months but sometimes works. The second is to skip the fight and move to a cash-pay option so treatment is not paused indefinitely. Some people pursue both in parallel. There is no single right answer, and this guide walks through what each path actually looks like so you can pick calmly.
Why insurers are denying more GLP-1 PAs in 2026
The landscape has genuinely shifted. Employer plans have been under budget pressure from GLP-1 utilization, and independent policy trackers have documented a wave of coverage tightening through 2025 and into 2026. The KFF state-by-state analysis of obesity treatment coverage is a useful map of how uneven coverage remains across public and private plans.
Several patterns are showing up in denial letters this year. Pharmacy benefit managers have raised BMI thresholds on some plans, so a patient who qualified in 2024 may not qualify under 2026 criteria. Step-therapy requirements have expanded: some plans now require patients to try older weight-management medications such as phentermine or Contrave first, and to document why those did not work. Others draw a sharper line between diabetes coverage and weight-loss coverage, so a tirzepatide prescription written for weight management may be denied even when tirzepatide would be covered for a patient with a type 2 diabetes diagnosis instead. Finally, an increasing number of employer plans have added explicit weight-loss carve-outs, meaning the benefit itself has been removed from the plan document.
Knowing which of these applies to your denial changes the whole strategy. That is why the first move is not to write an angry email — it is to ask specific questions.
7 questions to ask your insurer about the denial
Keep this list open when you call. Write down the representative's name, the date, and the reference number for the call. Ask for anything important to be sent to you in writing through your plan's secure portal.
- What was the specific denial reason? Ask them to identify the exact category: BMI threshold, step therapy, non-formulary status, medical necessity not established, or a plan exclusion. Each has a different appeal path.
- Is there an internal appeal process, and what is the deadline? Most plans give you a defined window from the date of the denial letter. Missing it can forfeit the appeal. Ask for the deadline in writing.
- What clinical documentation does the appeal require? Get the plan's medical-policy criteria and the specific documents needed: chart notes, BMI history, prior treatment attempts, labs, and a letter of medical necessity.
- Is there a formulary alternative that is covered? Sometimes Wegovy is covered when Zepbound is not, or vice versa. A licensed clinician should decide whether a switch is appropriate, but knowing the option exists is useful information.
- Does my plan have a weight-loss carve-out or exclusion? If the plan document explicitly excludes weight-loss medications, an appeal based on medical necessity for weight loss alone is unlikely to succeed. Confirm this early so you do not spend three months on paperwork that cannot win.
- Is there a medical-necessity pathway based on comorbidities? Documented hypertension, obstructive sleep apnea, prediabetes, or cardiovascular risk can sometimes open a different coverage door, even under plans that limit pure weight-loss coverage.
- What is the timeline for external independent review if the internal appeal fails? Ask when that clock starts, who runs the review in your state, and what documents are forwarded automatically versus what you have to resubmit.
If a representative cannot answer a question, ask to be transferred to the appeals or utilization-management team. You are entitled to the plan's written medical policy for the medication being denied. Request it, then share it with your clinician's office so the appeal can address each criterion directly.
How the appeal process actually works
Formal appeals move through predictable stages. The exact rules vary by plan type — a self-funded employer plan follows different regulations than a fully insured individual plan — but the general framework is consistent.
Realistic total timeline for a full three-step process: three to six months from the original denial. That is not a reason to skip the appeal — it is a reason to decide early whether you can wait that long without treatment, or whether you want to pursue a cash-pay option in parallel.
A few practical notes on paperwork. Most plans will accept documents through their secure portal or by fax; keep confirmation of every submission. If your clinician's office handles the appeal for you, ask them to copy you on the submitted packet so you have a full record if the case escalates to external review. If you receive a partial approval — for example, coverage limited to a lower dose or a shorter duration — that counts as a decision, and you may still appeal the piece that was denied. Read the letter closely rather than filing it away.
When the appeal is worth fighting
An appeal is generally worth the time when several things line up: you have an employer or commercial plan without an explicit weight-loss exclusion, you have documented comorbid conditions your clinician can cite in the letter of medical necessity, and your medication history shows either a failed step-therapy trial or a clinical reason step therapy is inappropriate. If you are willing to wait 90 days or more and you have a clinician's office that has done appeals before, the odds improve meaningfully.
An appeal is usually not worth it when the plan document contains an explicit weight-loss exclusion, when there are no documented comorbidities to cite, or when you need to start or resume treatment now and cannot pause for a multi-month process. In those cases, the honest answer is that a cash-pay lane is often the more practical route, even for people who intend to keep pressing HR at open enrollment. Choosing to skip the appeal is not giving up. It is picking the path that matches your actual timeline.
The cash-pay alternative: skip the fight
If you decide the appeal is not the right use of the next three months, the cash-pay landscape has changed enough in 2026 to be worth a fresh look. There are three broad lanes: brand-name Zepbound through LillyDirect, brand-name Zepbound through certain telehealth platforms, and compounded tirzepatide through telehealth. LillyDirect lists Zepbound self-pay pricing between $299 and $699 per month depending on dose. Compounded tirzepatide programs commonly list around $232 to $449 per month, depending on plan length and what is included.
The full breakdown lives in our 2026 tirzepatide cash-pay pricing guide, and a side-by-side of telehealth providers is in our telehealth pricing comparison. If your situation is specifically that insurance dropped Zepbound coverage mid-treatment, this guide walks through the mid-treatment version. If you were on a compounded plan through a national telehealth brand that has since exited, read this piece on what changed. Compounded medications are not FDA-approved products. The FDA's clarification on GLP-1 compounding is worth reading before choosing a compounded path.
How SkinnyVIP handles this
SkinnyVIP lists a $695 three-month plan (about $232 per month) or a $350 single-month plan. The stated price applies across the 2.5 mg to 15 mg dose range — it does not rise solely because the dose changes. There is no membership fee and no auto-renewal. Consultation, medication, supplies, and shipping are included. No insurance paperwork is required from you. Current details are on the SkinnyVIP pricing page.
SkinnyVIP offers telemedicine in all 50 states. A licensed clinician reviews your health history to determine whether treatment is appropriate; prescription is not guaranteed. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products. Individual results vary. If you want to see the clinical pathway alongside the numbers, review the $232/mo compounded tirzepatide overview.